Regenerative Medtech Is Becoming a Scale-and-Channel Consolidation Business
The most revealing healthcare development of the last two days may not be a new trial result or a new…
Cell Therapy Is Entering a Harsher Evidence-Governance Era
One of the most revealing biotech developments of the last forty-eight hours was not a clinical breakthrough but a regulatory…
Diagnostics Is Becoming a Distributed-Sampling Infrastructure Business
One of the more revealing healthcare developments of the last forty-eight hours did not come from a trial readout or…
Pharmacy Software Is Starting to Look Like Healthcare Infrastructure
One of the most overlooked healthcare developments of the last forty-eight hours came not from a drug trial, a reimbursement…
Pharmacy Software Is Starting to Look Like Healthcare Infrastructure
One of the most overlooked healthcare developments of the last forty-eight hours came not from a drug trial, a reimbursement…
Pharmacy Automation Is Becoming a Healthcare Infrastructure Play
The most interesting healthcare-operations development of the last forty-eight hours was LataMed AI and FARMASER entering a memorandum of understanding…
Surgical Robotics Is Entering Its Authorization Era
The most interesting healthcare technology development of the last forty-eight hours was Johnson & Johnson receiving FDA market authorization in…
Rare-Disease Progress Is Becoming a Data-Plumbing Problem
The most interesting biotech development of the last forty-eight hours is not a late-stage efficacy readout or a licensing deal.…
Early Cancer Detection Is Becoming an Evidence-Compounding Business
The most interesting biotech development of the last forty-eight hours is not a Phase 3 success or a takeover bid.…
Biotech Manufacturing Is Becoming a Network Game
The most interesting biotech development of the last forty-eight hours is not a clinical readout or a regulatory designation. It…
Radiopharma Is Becoming a Registration-Geography Business
The most interesting biotech development of the last forty-eight hours is not a dramatic efficacy surprise or another acquisition headline.…